Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: The role of PI3K, Akt and eNOS

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 2, 2003, Pages 185-193

  Bell, Robert M ^a   Yellon, Derek M ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Akt; Bradykinin; eNOS; Infarct size; Nitric oxide; PI3 kinase; Reperfusion injury

Indexed keywords

BRADYKININ; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANIMALS; BLOTTING, WESTERN; BRADYKININ; ENZYME INHIBITORS; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 0037325914     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2828(02)00310-3     Document Type: Article

References (42)

1. Yellon D.M., Baxter G.F. Reperfusion injury revisited. Is there a role for growth factor signalling in limiting lethal reperfusion injury? Trends Cardiovasc M. 9:2000;245-249.
2. Jonassen A.K., Brar B.K., Mjos O.D., Sack M.N., Latchman D.S., Yellon D.M. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol. 32:2000;757-764.
3. Jonassen A.K., Sack M.N., Mjos O.D., Yellon D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signalling. Circ Res. 89:2001;1191-1198.
4. Otani H., Yamamura T., Nakao Y., Hattori R., Kawaguchi H., Osako M., Imamura H. Insulin-like growth factor-I improves recovery of cardiac performance during reperfusion in isolated rat heart by a wortmannin-sensitive mechanism. J Cardiovasc Pharmacol. 35:2000;275-281.
5. Yamashita K., Kajstura J., Discher D.J., Wasserlauf B.J., Bishopric N.H., Anversa P., Webster K.A. Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ Res. 88:2001;609-614.
6. Hong F., Kwon S.J., Jhun B.S., Kim S.S., Ha J., Kim S.J., Sohn N.W., Kang C., Kang I. Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. Life Sci. 68:2001;1095-1105.
7. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 13:1999;2905-2927.
8. Baxter G.F., Mocanu M.M., Brar B.K., Latchman D.S., Yellon D.M. Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J Cardiovasc Pharmacol. 38:2001;930-939.
9. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 399:1999;601-605.
10. Guo Y., Jones W.K., Xuan Y.T., Tang X.L., Bao W., Wu W.J., Han H., Laubach V.E., Ping P., Yang Z., Qiu Y., Bolli R. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci USA. 96:1999;11507-11512.
11. Bell R.M., Smith C.C., Yellon D.M. Nitric oxide as a mediator of delayed pharmacological (A. receptor triggered) preconditioning; is eNOS masquerading as iNOS? Cardiovasc Res. 1:(53):2002;405-413.
12. Liu Y.H., Yang X.P., Sharov V.G., Sigmon D.H., Sabbath H.N., Carretero O.A. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension. 27:1996;7-13.
13. Linz W., Wiemer G., Scholkens B.A. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol. 24:1992;909-919.
14. Hartman J.C. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg. 60:1995;789-792.
15. Xie P., Browning D.D., Hay N., Mackman N., Ye R.D. Activation of NF-kappa B by bradykinin through a Galpha(q)- and Gbeta gamma-dependent pathway that involves phosphoinositide 3-kinase and Akt. J Biol Chem. 275:2000;24907-24914.
16. Li Y., Sato T. Dual signaling via protein kinase C and phosphatidylinositol 3'-kinase/Akt contributes to bradykinin B2 receptor-induced cardioprotection in guinea pig hearts. J Mol Cell Cardiol. 33:2001;2047-2053.
17. Ju H., Venema V.J., Marrero M.B., Venema R.C. Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase. J Biol Chem. 273:1998;24025-24029.
18. Bell R.M., Maddock H.L., Yellon D.M. The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart. Cardiovasc Res. 2002;. (in press).
19. Marber M.S., Mestril R., Chi S.H., Sayen M.R., Yellon D.M., Dillmann W.H. Overexpression of the rat inducible 70-kD heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury. J Clin Invest. 95:1995;1446-1456.
20. Xi L., Hess M.L., Kukreja R.C. Ischemic preconditioning in isolated perfused mouse heart: reduction in infarct size without improvement of post-ischemic ventricular function. Mol Cell Biochem. 186:1998;69-77.
21. Sumeray M.S., Yellon D.M. Characterisation and validation of a murine model of global ischaemia-reperfusion injury. Mol Cell Biochem. 186:1998;61-68.
22. Wall T.M., Sheehy R., Hartman J.C. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther. 270:1994;681-689. issn: 0022-3565.
23. Ebrahim Z., Yellon D.M., Baxter G.F. Bradykinin elicits 'second window' myocardial protection in rat heart through an NO-dependent mechanism. Am J Physiol Heart Circ Physiol. 281:2001;H1458-1464.
24. Kositprapa C., Ockaili R.A., Kukreja R.C. Bradykinin B2 receptor is involved in the late phase of preconditioning in rabbit heart. J Mol Cell Cardiol. 33:2001;1355-1362.
25. Ritchie R.H., Marsh J.D., Schiebinger R.J. Bradykinin-stimulated protein synthesis by myocytes is dependent on the MAP kinase pathway and p70(S6K). Am J Physiol. 276:1999;H1393-1398.
26. Fleming I., Fisslthaler B., Dimmeler S., Kemp B.E., Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res. 88:2001;E68-E75.
27. Harris M.B., Ju H., Venema V.J., Liang H., Zou R., Michell B.J., Chen Z.P., Kemp B.E., Venema R.C. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem. 276:2001;16587-16591.
28. Igarashi J., Bernier S.G., Michel T. Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J Biol Chem. 276:2001;12420-12426.
29. Bernier S.G., Haldar S., Michel T. Bradykinin-regulated interactions of the mitogen-activated protein kinase pathway with the endothelial nitric-oxide synthase. J Biol Chem. 275:2000;30707-30715.
30. Cao Y., Hotta Y., Shioi K., Nagata Y., Kawai N., Ishikawa N. Protective effects of FK409, a novel nitric oxide donor, against postischemic myocardial dysfunction in guinea-pig hearts. J Cardiovasc Pharmacol. 38:2001;593-605.
31. Mohara J., Oshima K., Tsutsumi H., Takeyoshi I., Matsumoto K., Morishita Y. FK409 ameliorates ischemia-reperfusion injury in heart transplantation following 12-hour cold preservation. J Heart Lung Transplant. 19:2000;694-700.
32. Rakhit R.D., Mojet M.H., Marber M.S., Duchen M.R. Mitochondria as targets for nitric oxide-induced protection during simulated ischemia and reoxygenation in isolated neonatal cardiomyocytes. Circulation. 103:2001;2617-2623.
33. Dimmeler S., Rippmann V., Weiland U., Haendeler J., Zeiher A.M. Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide. Circ Res. 81:1997;970-976.
34. Rossig L., Fichtlscherer B., Breitschopf K., Haendeler J., Zeiher A.M., Mulsch A., Dimmeler S. Nitric oxide inhibits caspase-3 by S-nitrosation in vivo. J Biol Chem. 274:1999;6823-6826.
35. Csont T., Szilvassy Z., Fulop F., Nedeianu S., Pali T., Tosaki A., Dux L., Ferdinandy P. Direct myocardial anti-ischaemic effect of GTN in both nitrate-tolerant and nontolerant rats: a cyclic GMP-independent activation of KATP. Br J Pharmacol. 128:1999;1427-1434.
36. Brookes P.S., Salinas E.P., Darley-Usmar K., Eiserich J.P., Freeman B.A., Darley-Usmar V.M., Anderson P.G. Concentration-dependent effects of nitric oxide on mitochondrial permeability transition and cytochrome c release. J Biol Chem. 275:2000;20474-20479.
37. DelBel E.A., Padovan A.P., Padovan G.J., Sellinger O.Z., Martins A.R. Enzymatic inactivation of bradykinin By rat brain neuronal perikarya. Cell Mol Neurobiol. 9:1989;379-400.
38. Yang X.P., Liu Y.H., Peterson E., Carretero O.A. Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/reperfusion injury: the role of kinins. J Cardiovasc Pharmacol. 29:1997;250-256.
39. Yang X.P., Liu Y.H., Shesely E.G., Bulagannawar M., Liu F., Carretero O.A. Endothelial nitric oxide gene knockout mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension. 34:1999;24-30.
40. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 345:1995;669-685.
41. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 343:1994;1115-1122.
42. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J M. 342:2000;145-153.